STAT28d
Biogen partners with Stoke Therapeutics to sell severe epilepsy drug
From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of ...
STAT28d
Biogen partners with Stoke Therapeutics on drug for severe epilepsy
Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of epilepsy, outside the U.S., the ...
FierceBiotech27d
Biogen pays Stoke $165M, bagging Dravet prospect to fire up late-phase pipeline
Biogen has refueled its R&D engine, paying Stoke Therapeutics $165 million upfront for ex-U.S. rights to a phase 3-ready molecule that could become the first disease-modifying treatment for Dravet ...
Benzinga.com13d
What the Options Market Tells Us About Biogen
High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking ...
Benzinga.com7d
Decoding Biogen's Options Activity: What's the Big Picture?
Investors with a lot of money to spend have taken a bullish stance on Biogen BIIB. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...
MarketWatch24d
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a treatment for Dravet syndrome, a severe form of epilepsy that starts in childhood.
Nasdaq25d
Biogen Stock Is Mutating Into a Value Play
Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology ...
Yahoo Finance21d
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side ...
PMLiVE26d
Biogen gains rights to Stoke’s Dravet syndrome candidate in deal worth $550m
Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet syndrome, with the deal worth $550m. Up to 38,000 people in the US, UK, EU and ...
Business Wire27d
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with ...
CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the ...
pharmaphorum3d
Biogen exits biosimilar JV with Samsung, raising $2.3bn
The two companies have been partnered on Samsung Bioepis for the best part of a decade, successfully bringing six biosimilar copies of biologic drugs to regulatory approval, but Biogen now says it ...